Loading
Loading
40 Million Medical Imaging Procedures Per Year Depend on a Radioactive Isotope Made in Aging Cold War-Era Reactors
Technetium-99m (Tc-99m) is used in approximately 40 million medical diagnostic imaging procedures annually worldwide — 80% of all nuclear medicine scans — for detecting heart disease, cancer, bone disorders, and organ function. Tc-99m has a 6-hour half-life, meaning it cannot be stockpiled and must be generated on-demand by decay of its parent isotope molybdenum-99 (Mo-99, 66-hour half-life). Nearly all global Mo-99 production comes from irradiating uranium targets in a handful of aging research reactors, most built in the 1960s: NRU (Canada, permanently shut down 2018), HFR (Netherlands, operational since 1961), BR2 (Belgium, 1961), SAFARI-1 (South Africa, 1965), and OPAL (Australia, 2007). Scheduled and unscheduled shutdowns of these reactors have repeatedly caused global Tc-99m shortages, most severely in 2009-2010 when simultaneous shutdowns of NRU and HFR eliminated ~70% of global supply, forcing hospitals to cancel or delay thousands of cardiac and cancer diagnostic procedures.
Tc-99m is not a niche isotope — it is the workhorse of diagnostic nuclear medicine. A single missed cardiac perfusion scan can delay diagnosis of coronary artery disease; aggregate shortages affect millions of patients. The current supply chain is structurally fragile: 5 reactors (now effectively 4 since NRU's permanent shutdown) supply the global market, most are approaching or past their designed operational lifetimes, and building a new research reactor takes 10-15 years and costs $500M-$1B. The NASEM report identified the transition away from highly enriched uranium (HEU) targets as an additional complication — nonproliferation agreements require conversion to low-enriched uranium (LEU) targets, which produce Mo-99 less efficiently and require modified processing chemistry. The U.S. currently has no domestic Mo-99 production and depends entirely on imports.
SHINE Medical Technologies (Wisconsin) has developed a subcritical fission approach using deuterium-tritium neutron generators to irradiate LEU targets without a reactor — a fundamentally different production method. SHINE began limited Mo-99 production in 2024, but scaling to meet even U.S. demand (which is ~50% of global use) requires multiple production modules operating simultaneously, and the supply chain for processing irradiated targets and distributing Mo-99/Tc-99m generators remains reliant on a small number of processing facilities. Direct Tc-99m production via cyclotron irradiation of Mo-100 targets (⁹⁹Mo + p → ⁹⁹ᵐTc) has been demonstrated in Canada and is operational for regional supply, but cyclotron-produced Tc-99m cannot be distributed via the generator system that the global supply chain is built around — each hospital would need access to a nearby cyclotron, requiring complete infrastructure redesign. Photonuclear production (⁹⁹Mo + γ → ⁹⁸Mo + n) using electron accelerators has been demonstrated but produces Mo-99 at low specific activity, requiring modifications to existing generator and radiopharmacy infrastructure.
Scaling of non-reactor Mo-99 production (SHINE-type neutron generators or accelerator-based methods) to commercial volumes with economics competitive with reactor production. This requires both production technology maturation and processing/distribution infrastructure development. Standardized low-enriched uranium target processing chemistry that can be implemented at multiple production facilities, reducing dependence on any single site. Advanced Tc-99m generator designs that work with low-specific-activity Mo-99, enabling compatibility with accelerator-produced feedstock. Longer-term: development of alternative radiopharmaceuticals using isotopes with less fragile supply chains (e.g., Ga-68 from Ge-68/Ga-68 generators, Cu-64 from cyclotrons), though replacing 40 years of Tc-99m clinical protocols is a massive adoption challenge.
A student team could model the Mo-99/Tc-99m supply chain as a network reliability problem, simulating the impact of reactor shutdowns and production facility disruptions on regional availability, and identifying optimal locations for new production capacity. Alternatively, a team in nuclear or chemical engineering could design and simulate an optimized LEU target irradiation and processing workflow for a university research reactor, assessing the feasibility of producing hospital-scale Mo-99 quantities from a small (1-10 MW) reactor. Relevant disciplines: nuclear engineering, chemical engineering, supply chain management, health systems, radiochemistry.
- The `temporal:window` tag (added in Wave 0 structural audit) reflects carrier mortality: the aging Cold War-era reactors (built 1961-1965) ARE the production capability, and they are mortal. NRU was permanently shut down in 2018; the remaining reactors are past their designed lifetimes with 10-15 years and $500M-$1B to build replacements. The window is the remaining operational life of these irreplaceable facilities. - The NASEM Mo-99 reports (2009, 2016) explicitly identified the fragility of the global Mo-99 supply chain as a critical health infrastructure vulnerability. - The `constraint:supply-chain` tag is the primary constraint: global Mo-99 production is concentrated in 4-5 aging reactors, with no rapid-response backup if multiple facilities go offline simultaneously. - The `constraint:regulatory` tag reflects the HEU-to-LEU conversion mandate: the American Medical Isotopes Production Act of 2012 requires that U.S.-sourced Mo-99 be produced without HEU, constraining production methods. - The `failure:ignored-context` tag captures the historical assumption that research reactors would always be available — the medical imaging community built a $10+ billion/year clinical infrastructure on a supply chain it did not control and did not diversify. - The `failure:unviable-economics` tag reflects the paradox that Mo-99 is essential but unprofitable to produce: reactor operators historically provided Mo-99 as a byproduct of research operations, and the true production cost was never fully recovered in market prices, discouraging commercial investment in alternatives. - Cross-domain connection: shares the single-source-critical-infrastructure structure with space-ice-giant-mission-power-longevity (Pu-238 supply concentration), energy-grid-transformer-supply-chain-crisis (GOES steel and transformer manufacturing), and space-radiation-hardened-computing-gap (two-company rad-hard processor market).
"Molybdenum-99 for Medical Imaging," National Academies of Sciences, Engineering, and Medicine, 2016. https://doi.org/10.17226/23563, accessed 2026-02-16. Also: "Medical Isotope Production Without Highly Enriched Uranium," NASEM, 2009; OECD/NEA "The Supply of Medical Radioisotopes" reports, 2019-2024.